SOPHiA GENETICS (NASDAQ:SOPH) President Sells $21,143.92 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) President Ross Muken sold 4,442 shares of the stock in a transaction dated Monday, April 13th. The stock was sold at an average price of $4.76, for a total transaction of $21,143.92. Following the transaction, the president owned 685,232 shares of the company’s stock, valued at approximately $3,261,704.32. This represents a 0.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ross Muken also recently made the following trade(s):

• On Tuesday, April 14th, Ross Muken sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.96, for a total transaction of $13,888.00.
• On Friday, April 10th, Ross Muken sold 3,687 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.69, for a total transaction of $17,292.03.
• On Thursday, April 9th, Ross Muken sold 1,950 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total transaction of $9,243.00.
• On Wednesday, April 8th, Ross Muken sold 2,786 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total transaction of $13,484.24.
• On Tuesday, April 7th, Ross Muken sold 2,424 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total transaction of $11,804.88.
• On Thursday, March 19th, Ross Muken sold 1,183 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total transaction of $5,666.57.

SOPHiA GENETICS Trading Up 1.0%

Shares of NASDAQ:SOPH opened at $5.12 on Friday. SOPHiA GENETICS SA has a 52-week low of $2.58 and a 52-week high of $5.70. The company has a market capitalization of $350.67 million, a P/E ratio of -10.04 and a beta of 1.04. The company has a 50-day simple moving average of $4.75 and a 200 day simple moving average of $4.72. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.84 and a current ratio of 1.96.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.The business had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. Sell-side analysts forecast that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SOPH. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Guggenheim lifted their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, BTIG Research lifted their price target on SOPHiA GENETICS from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $7.50.

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Strategic commercial win — Mount Sinai Health System will adopt SOPHiA GENETICS’ AI-powered SOPHiA DDM™ platform to support precision cancer care and genomic testing at a major NCI-designated center, which could drive recurring software volume and credibility with large U.S. health systems. Mount Sinai collaboration
• Positive Sentiment: Sector tailwind — coverage highlighting Mount Sinai’s use of AI to speed genomic testing reinforces demand for AI-driven genomics platforms like SOPHiA DDM, supporting adoption and long-term revenue potential. Healthcare IT News
• Positive Sentiment: Analyst interest — several firms have set $7.00 targets and issued buy opinions (e.g., Guggenheim, BTIG), giving investors an upside reference versus current levels.
• Neutral Sentiment: Insider selling activity — multiple insiders (CEO Jurgi Camblong, President Ross Muken and others) disclosed sales totaling tens of thousands of shares in mid-April. All trades were executed under pre-arranged Rule 10b5-1 plans and many were described as tax-withholding sales tied to vested awards, which reduces immediate governance concern but increases float. SEC Form 4 (example)
• Negative Sentiment: Underlying profitability risks — the company reported a March-quarter EPS miss (reported ($0.28) vs. consensus ($0.20)), with negative net margins and a substantial negative ROE. Analysts still expect FY losses (consensus around -0.96 EPS), highlighting ongoing path-to-profitability concerns that can cap multiple expansion. Earnings & metrics

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after acquiring an additional 5,432,871 shares during the period. Akre Capital Management LLC raised its holdings in SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after acquiring an additional 1,481,636 shares during the period. Alta Wealth Advisors LLC bought a new position in SOPHiA GENETICS in the 3rd quarter valued at about $6,708,000. Royce & Associates LP bought a new position in SOPHiA GENETICS in the 4th quarter valued at about $2,009,000. Finally, 1492 Capital Management LLC bought a new position in SOPHiA GENETICS in the 4th quarter valued at about $973,000. 31.59% of the stock is owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.